Trial · NCT01552928
Participant flow48
How many started, completed or left each group, period by period.
1 to 20 of 48
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Period 1 | STARTED | Anag 0.5 mg, Then Anag 2.5 mg, Then Placebo, Then Mox 400 mg | 14 | |
| Period 1 | STARTED | Anag 2.5 mg, Then Mox 400 mg, Then Anag 0.5 mg, Then Placebo | 15 | |
| Period 1 | STARTED | Mox 400 mg, Then Placebo, Then Anag 2.5 mg, Then Anag 0.5 mg | 15 | |
| Period 1 | STARTED | Placebo, Then Anag 0.5 mg, Then Mox 400 mg, Then Anag 2.5 mg | 16 | |
| Period 1 | COMPLETED | Anag 0.5 mg, Then Anag 2.5 mg, Then Placebo, Then Mox 400 mg | 14 | |
| Period 1 | COMPLETED | Anag 2.5 mg, Then Mox 400 mg, Then Anag 0.5 mg, Then Placebo | 15 | |
| Period 1 | COMPLETED | Mox 400 mg, Then Placebo, Then Anag 2.5 mg, Then Anag 0.5 mg | 15 | |
| Period 1 | COMPLETED | Placebo, Then Anag 0.5 mg, Then Mox 400 mg, Then Anag 2.5 mg | 16 | |
| Period 1 | NOT COMPLETED | Anag 0.5 mg, Then Anag 2.5 mg, Then Placebo, Then Mox 400 mg | 0 | |
| Period 1 | NOT COMPLETED | Anag 2.5 mg, Then Mox 400 mg, Then Anag 0.5 mg, Then Placebo | 0 | |
| Period 1 | NOT COMPLETED | Mox 400 mg, Then Placebo, Then Anag 2.5 mg, Then Anag 0.5 mg | 0 | |
| Period 1 | NOT COMPLETED | Placebo, Then Anag 0.5 mg, Then Mox 400 mg, Then Anag 2.5 mg | 0 | |
| Period 2 | STARTED | Anag 0.5 mg, Then Anag 2.5 mg, Then Placebo, Then Mox 400 mg | 14 | |
| Period 2 | STARTED | Anag 2.5 mg, Then Mox 400 mg, Then Anag 0.5 mg, Then Placebo | 15 | |
| Period 2 | STARTED | Mox 400 mg, Then Placebo, Then Anag 2.5 mg, Then Anag 0.5 mg | 15 | |
| Period 2 | STARTED | Placebo, Then Anag 0.5 mg, Then Mox 400 mg, Then Anag 2.5 mg | 16 | |
| Period 2 | COMPLETED | Anag 0.5 mg, Then Anag 2.5 mg, Then Placebo, Then Mox 400 mg | 14 | |
| Period 2 | COMPLETED | Anag 2.5 mg, Then Mox 400 mg, Then Anag 0.5 mg, Then Placebo | 15 | |
| Period 2 | COMPLETED | Mox 400 mg, Then Placebo, Then Anag 2.5 mg, Then Anag 0.5 mg | 15 | |
| Period 2 | COMPLETED | Placebo, Then Anag 0.5 mg, Then Mox 400 mg, Then Anag 2.5 mg | 16 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01552928/flow